Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100147 | 0.88 | MAPT (0.49) | PTPN1RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3105614 | 0.88 | PTPN1 (0.62) | PTPN1RAB9AMEN1KMT2APOLB | |
| SCHEMBL3092704 | 0.86 | NR1H4 (0.46) | PTPN1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3105900 | 0.85 | PTPN1 (0.41) | PTPN1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3083744 | 0.84 | NPC1 (0.53) | RAB9AMEN1KMT2ANPC1TDP1 | |
| SCHEMBL3103323 | 0.84 | NPC1 (0.48) | PTPN1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3087236 | 0.83 | MEN1 (0.51) | RAB9AMEN1KMT2ANPC1DGAT1 | |
| SCHEMBL3100204 | 0.82 | MEN1 (0.55) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3098838 | 0.82 | ADAMTS4 (0.61) | PTPN1MEN1KMT2APOLBMITF | |
| SCHEMBL3102885 | 0.82 | SMN1; SMN2 (0.55) | RAB9AMEN1KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | claimed |
| EP-1912634-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Healthcare, LLC (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | PTPN1 2680/4885RAB9A 1741/4885MEN1 4210/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | PTPN1 2680/4885RAB9A 1741/4885MEN1 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.